Spanish version of the mHealth app usability questionnaire (MAUQ) and adaptation to breastfeeding support apps

Quifer-Rada, Paola; Aguilar-Camprubí, Laia; Gómez-Sebastià, Ignasi; Padró-Arocas, Alba; Mena‐Tudela, Desirée

doi:10.1016/j.ijmedinf.2023.105062

Cited by 8 publications

(3 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to a recent study the MAUQ is reliable (Cronbach α = 0.89), valid, relevant, clear, and comprehensible for Spanish people. 49 …”

Section: Methodsmentioning

confidence: 99%

Study protocol for a three-arm randomized controlled trial investigating the effectiveness, cost-utility, and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia

Gallego,

Serrat,

Royuela-Colomer

et al. 2024

DIGITAL HEALTH

View full text Add to dashboard Cite

Objective Fibromyalgia (FM) is a prevalent pain syndrome with significant healthcare and societal costs. The aim of the SMART-FM-SP study is to determine the effectiveness, cost-utility, and physiological effects in patients with FM of a digital intervention (STANZA®) currently marketed in the United States, which delivers smartphone-based, fully self-guided Acceptance and Commitment Therapy (Digital ACT) for treating FM-related symptoms. Methods A single-site, parallel-group, superiority, randomized controlled trial (RCT) will be conducted, including a total of 360 adults diagnosed with FM. Individuals will be randomly allocated (1:1:1) to treatment as usual (TAU), to TAU plus 12 weeks of treatment with Digital ACT, or to TAU plus 12 weeks of treatment with digital symptom tracking (i.e. FibroST). Participants will be assessed at baseline, post-treatment, and 6-month follow-up. An intention-to-treat analysis using linear mixed models will be computed to analyze the effects of Digital ACT on functional impairment (primary outcome), as measured by the Fibromyalgia Impact Questionnaire Revised at 6 months from the inception of the treatment. Secondary outcomes include impression of change, symptoms of distress, pain catastrophising, quality of life, cost-utility, and selected biomarkers (cortisol and cortisone, immune-inflammatory markers, and FKBP5 gene polymorphisms). The role of ACT-related processes of change will be tested with path analyses. Conclusions This study is the first RCT that tests Digital ACT for Spanish patients with FM. Results will be important not only for patients and clinicians, but also for policy makers by examining the cost-utility of the app in a public healthcare context.

show abstract

“…According to a recent study the MAUQ is reliable (Cronbach α = 0.89), valid, relevant, clear, and comprehensible for Spanish people. 49 …”

Section: Methodsmentioning

confidence: 99%

Study protocol for a three-arm randomized controlled trial investigating the effectiveness, cost-utility, and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia

Gallego,

Serrat,

Royuela-Colomer

et al. 2024

DIGITAL HEALTH

View full text Add to dashboard Cite

show abstract

“…The MHealth App Usability Questionnaire (MAUQ) [21] was designed to assess mHealth app usability, encompassing aspects like ease of use, e ciency, learnability, and satisfaction. Although the MAUQ has been translated and adapted into various versions [22][23][24], it still has limitations because individuals over 65 years old or those with limited education were excluded during the development process. Other existing tools also suffer from shortcomings, such as inadequate sampling methods, a lack of a robust theoretical framework, and incomplete evaluations [25,26].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a mobile health application usability scale for older adults with chronic diseases

Yu,

Qiu,

Wang

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Chronic diseases are one of the leading causes of disability and death in people over 60 years old. Mobile health applications can revolutionize healthcare delivery and management of chronic conditions and reduce healthcare costs. Unfortunately, many of these applications are not designed for elderly patients with chronic diseases. Therefore, it is crucial to create a reliable and specialized tool that developers and researchers can use to assess the usability of mobile (mHealth) applications designed specifically for elderly patients. Objective To develop and validate a mHealth application usability evaluation scale for elderly patients with chronic diseases. Methods We developed the first edition of the scale from March to September 2022 through literature review, interview, team discussion, and the Delphi method. Between October and December 2022, the improved scale after a pilot test was used to conduct surveys in Guangzhou, Guangdong, China, to analyze and screen items using the Item Discrimination Index, Correlation coefficient, Internal consistency test, and exploratory factor analysis. From October 2022 to February 2023, we completed the data collection and evaluation of the reliability and validity of the scale. Results The finalized scale included six dimensions and 23 items. Item-level content validity indices and the average scale content validity index ranged from 0.85–1. The validation evaluation showed that the scale has a good fit, with a χ2/df ratio of 1.728 and various fit indices ranging from 0.817–0.928. The values of Average Variance extraction and Composite Reliability also met the recommended criteria, with a value greater than 0.4 and 0.6, respectively. Additionally, the Cronbach's α coefficient for the full scale and subscales ranged from 0.758–0.911, indicating good internal consistency. Conclusions The usability scale for elderly patients with chronic diseases is a reliable and valid instrument. It fills gaps in existing tools, offering a comprehensive assessment of mHealth app usability among target audience. It has the potential to improve mHealth app design and promote age-appropriateness of healthcare delivery.

show abstract

“…and adapted into various versions [22][23][24], it still has limitations because individuals over 65 years old or those with limited education were excluded during the development process. Other existing tools also suffer from shortcomings, such as inadequate sampling methods, a lack of a robust theoretical framework, and incomplete evaluations [25,26].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of a mobile health application usability scale for older adults with chronic diseases (Preprint)

Yu,

Qiu,

Wang

et al. 2023

JMIR Aging

View full text Add to dashboard Cite

Background: Chronic diseases are one of the leading causes of disability and death in people over 60 years. Mobile health applications can revolutionize healthcare delivery and management of chronic conditions as well as reduce healthcare costs. Unfortunately, many of these applications are not designed for elderly patients with chronic diseases. Therefore, it is crucial to create a reliable and specialized tool that developers and researchers can use to assess the usability of mobile (mHealth) applications designed specifically for elderly patients.Objective: To develop and validate a mHealth application usability evaluation scale for elderly patients with chronic diseases. Methods:We developed the first edition of the scale from March to September 2022 through literature review, interview, team discussion, and the Delphi method. Between October and December 2022, the improved scale after a pilot test was used to conduct surveys in Guangzhou, Guangdong, China, to analyze and screen items using the Item Discrimination Index, Correlation coefficient, Internal consistency test, and exploratory factor analysis. From October 2022 to February 2023, we completed the data collection and evaluation of the reliability and validity of the scale. Results:The finalized scale included six dimensions and 23 items. Item-level content validity indices and the average scale content validity index ranged from 0.85-1. The validation evaluation showed that the scale has a good fit, with a ?2/df ratio of 1.728 and various fit indices ranging from 0.817-0.928. The AVE and CR values also met the recommended criteria, with a value greater than 0.4 and 0.6, respectively. Additionally, the Cronbach's ? coefficient for the full scale and subscales ranged from 0.758-0.911, indicating good internal consistency. Conclusions:The mHealth application usability evaluation scale for older adults with chronic disease was developed with rigorous steps, showing good reliability and validity. The scale can be used to evaluate the usability of mHealth among older adults and promote the age-appropriateness of mHealth.

show abstract

Spanish version of the mHealth app usability questionnaire (MAUQ) and adaptation to breastfeeding support apps

Cited by 8 publications

References 31 publications

Study protocol for a three-arm randomized controlled trial investigating the effectiveness, cost-utility, and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia

Study protocol for a three-arm randomized controlled trial investigating the effectiveness, cost-utility, and physiological effects of a fully self-guided digital Acceptance and Commitment Therapy for Spanish patients with fibromyalgia

Development and validation of a mobile health application usability scale for older adults with chronic diseases

Development and validation of a mobile health application usability scale for older adults with chronic diseases (Preprint)

Contact Info

Product

Resources

About